Verve Therapeutics Inc (VERV) USD0.001

Sell:$4.13Buy:$4.14$0.42 (9.19%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$4.13
Buy:$4.14
Change:$0.42 (9.19%)
Market closed | Prices delayed by at least 15 minutes
Sell:$4.13
Buy:$4.14
Change:$0.42 (9.19%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.

Key people

Andrew D. Ashe
President, Chief Operating Officer, General Counsel
Sekar Kathiresan
Chief Executive Officer, Director
Allison Dorval
Chief Financial Officer
Joan Nickerson
Chief Administrative Officer
Troy Lister
Chief Scientific Officer
Frederick T. Fiedorek
Chief Medical Officer
Burt A. Adelman
Independent Chairman of the Board
Ourania Tatsis
Director
Lonnel Coats
Independent Director
Alexander G. Cumbo
Independent Director
Michael F. Maclean
Independent Director
Click to see more

Key facts

  • EPIC
    VERV
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US92539P1012
  • Market cap
    $405.80m
  • Employees
    274
  • Shares in issue
    88.80m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.